Compare Inovio Pharmaceuticals Inc (INO) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.13 (market cap $112.19M), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.22 (market cap $4.35B). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is far larger — about 38.8× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| INO | SJNK | |
|---|---|---|
Market Cap | $112.19M | $4.35B |
Volume | 3,201,278 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $2.65 | $25.57 |
52-Week Low | $0.66 | $24.13 |
Typical Hold Time | 43 Days | 41 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.20, down 0.21% with a bearish technical outlook. The ETF shows strong institutional interest despite recent selling activity by some firms. Dividend distributions remain consistent with recent payments of $0.14-$0.15 per share, providing income appeal in a rising rate environment.
The ETF faces headwinds from technical weakness but maintains income appeal through consistent dividends. Key risks include interest rate sensitivity and institutional selling pressure, while the current yield advantage over Treasuries presents opportunity for income-focused investors in the high-yield bond space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
